Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Inclusion Criteria:

• Histological or cytological confirmation of NSCLC.

• Part A

1. Clinical Stage II-IIIB (N2) treated with presurgical chemoimmunotherapy,with residual tumor present at time of surgery. Patients with a pathologiccomplete response are not eligible.
2. Pathologic Stage II-IIIB (N2) NSCLC treated with initial upfrontresection.

• Part B - Clinical Stage III, unresectable NSCLC, without progression onconcurrent platinum-based chemoradiotherapy.

• Must have disease with evidence of KRAS G12C mutation.

• Must have known programmed death-ligand 1 (PD-L1) expression

• Must have an ECOG performance status of 0 or 1.

• Able to swallow oral medication.

• Must have adequate laboratory parameters.

• Contraceptive use should be consistent with local regulations for thoseparticipating in clinical studies.

• Women of childbearing potential must

• Have a negative pregnancy test.

• Not be breastfeeding during treatment

Exclusion Criteria:

• Have known changes in the EGFR or ALK genes.

• Have another type of cancer that is progressing or required active treatment withinthe past 2 years before screening.

• Have an active autoimmune disease that required systemic treatment in the past 2years. Endocrine replacement therapy is allowed.

• Had any immune-related side effect or allergic reaction (Grade 3 or higher) from aprevious immunotherapy medicine, or any immune-related side effect greater thanGrade 1 that has not resolved. This does not apply for people with hormone-relateddiseases who are now on stable hormone replacement therapy.